OSTEOARTHRITIS
Zoledronic acid for postmenopausal osteoporosis reduces fracture risk and improves BMD
This report has been verified
by one or more authors of the
original publication.
J Bone Miner Metab. 2011 May;29(3):328-33. doi: 10.1007/s00774-010-0223-y. Epub 2010 Oct 5
323 Chinese women were randomized to evaluate the efficacy and safety of a once-yearly zoledronic acid treatment for postmenopausal osteoporosis. Patients received either annual infusions of zoledronic acid or placebo for 3 consecutive years and were assessed at the end of this period. Results revealed that zoledronic acid reduced the risk of vertebral fractures and increased the bone mineral density of Chinese women with postmenopausal osteoporosis.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
